IMBRUVICA® (ibrutinib) capsules
IMBRUVICA® (ibrutinib) capsules
Table 7: Non-Hematologic Adverse Reactions in ≥ 10% of Patients with
Waldenström’s Macroglobulinemia (N=63) (continued)
Table 4: Treatment-Emergent* Decrease of Hemoglobin, Platelets,
or Neutrophils in Patients with CLL